- Reference code :
- wf340
- Published date :
-
04 September 2000
- Expired date :
-
21 January 2028
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved its breast cancer treatment Arimidex™ as a new treatment option for post-menopausal women first diagnosed with advanced or locally advanced breast cancer whose cancers are hormone receptive. Arimidex is the first aromatase inhibitor to be approved for first-line treatment in the U.S.
Previously, Arimidex was only approved for use after disease progression following tamoxifen treatment. Two pivotal studies found that Arimidex was as effective and well tolerated as tamoxifen when prescribed at the time of diagnosis for women with advanced breast cancer.
Arimidex was first approved in 1996 as a treatment for post-menopausal women with advanced breast cancer who progressed following hormonal treatment with tamoxifen. Arimidex is a non-steroid aromatase inhibitor, which works to lower the amount of circulating estrogens in the body. Earlier this year, the drug gained approval in several European countries for first-line use in post-menopausal women with advanced disease.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $15 billion and leading positions in sales of gastrointestinal, oncology, anesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.
Further enquires to:
|
Steve Brown +44 (0)20 7304 5033 Lucy Williams +44 (0)20 7304 5034 |
Note to News Editors: |
|
|
|
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 06:01 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
